The author declares no conflicts of interest.
DEVELOPMENTAL BIOLOGY: FRONTIERS FOR CLINICAL GENETICS
An emerging role for Wnt and GSK3 signaling pathways in schizophrenia
Article first published online: 1 APR 2013
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
Volume 83, Issue 6, pages 511–517, June 2013
How to Cite
An emerging role for Wnt and GSK3 signaling pathways in schizophrenia..
- Issue published online: 23 APR 2013
- Article first published online: 1 APR 2013
- Accepted manuscript online: 4 FEB 2013 02:04PM EST
- Manuscript Revised: 21 JAN 2013
- Manuscript Accepted: 21 JAN 2013
- Manuscript Received: 4 JAN 2013
- brain development;
- wnt signaling
Schizophrenia is a disabling illness with limited treatment options. The underlying pathophysiology remains unknown, partially due to its heterogeneous nature, and a lack of understanding of the biological functions of genetic risk factors. Several signaling pathways have been implicated, however, with the varying degrees of support. In this article, I will focus on the converging evidence supporting a prominent role for Wnt and glycogen synthase kinase 3 (GSK3) signaling in the biological bases of schizophrenia. This includes current pharmacological therapies that target GSK3, animal model and cell-based studies, and recent human genetic findings that implicate Wnt and GSK3 signaling.